Table 3.

Prophylactic dose-response comparison of m2C9 and 2C9-H4 IgG in 17D-204 challenged AG129 mice.

Group	μg Antibody^a	Survivors/Total Mice (% Survivors)	Brain Viral Load^b		AST^c
Group	μg Antibody^a	Survivors/Total Mice (% Survivors)	Survivors	Dead	AST^c
PBS Controls	n/a	0/5 (0)	n.a.	6.9 (0.6)	18.8 (5.9)
2C9-H4 IgG	127	4/5 (80)^d	2.2 (2.5)^d,^e	6.74	28.8 (4.9)^d
	12.7	10/10 (100)^d	1.0 (0.4)^d	n.a.	31 (0)d
	1.27	2/10 (20)	5.1 (0.7)^d,^e	6.7 (0.3)	19.2 (6.9)
m2C9 IgG	127	5/5 (100)^d	0.9 (0.3)^d	n.a.	31 (0)^d
	12.7	8/10 (80)^d	1.5 (1.3)^d,^e	6.5 (0.1)	27.0 (6.9)^d
	1.27	6/10 (60)^d	3.9 (2.4)^d,^e	6.7 0.5)	26.1 (6.8)^d

Mice were inoculated i.p. with varying doses of purified MAb 24 hours prior to i.p. virus challenge. Experiments were terminated at 31 days post-infection.

Expressed as mean (s.d.) of the genomic copies (log₁₀)/g tissue.

Average survival time (AST) in days (s.d.).

ρ <0.05 by two-tailed t-test statistic vs. paired PBS control mice.

ρ <0.05 by two-tailed t-test statistic vs. paired dead mice.